Advanced Medical Optics Adds to Its Market-Leading Portfolio of Refractive IOLs With FDA Approval of the ReZoom Multifocal Refra

Advanced Medical Optics Adds to Its Market-Leading Portfolio of
Refractive IOLs With FDA Approval of the ReZoom Multifocal Refractive Lens



SANTA ANA, Calif., March 28  /PRNewswire-FirstCall/ -- Advanced Medical Optics,
Inc. (AMO) (NYSE:AVO), a global leader in ophthalmic surgical devices and eye
care products, today added to its market-leading portfolio of refractive
intraocular lenses (IOLs) with the announcement that the U.S. Food and Drug
Administration (FDA) has approved the ReZoom(TM) multifocal refractive IOL for
cataract patients.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO)

The ReZoom(TM) IOL is a new design and next generation acrylic three-piece
multifocal IOL.  The ReZoom(TM) IOL Balanced View Optics(TM) distribute light
over five optical zones for enhanced restoration of visual function, providing
distance, intermediate and near vision for reduced spectacle dependence.  This
allows the lens to match its performance characteristics with the lifestyle
demands of the patient.

"The ReZoom(TM) multifocal lens adds to our portfolio of refractive IOLs that
already includes innovative technologies such as the Verisyse(TM) phakic IOL
and the Tecnis(R) Multifocal lens, which is currently being evaluated in a
clinical trial in the U.S.," said AMO President and CEO Jim Mazzo.  "With our
expansive portfolio of refractive IOLs, AMO's strategy is to lead in building
the burgeoning global refractive marketplace."

Both the ReZoom(TM) and Tecnis(R) Multifocal IOLs have CE Mark approval in
Europe for treatment of presbyopia.

About Advanced Medical Optics (AMO)

AMO is a global leader in the development, manufacturing and marketing of
ophthalmic surgical and eye care products.  The company focuses on developing a
broad suite of innovative technologies and devices to address a wide range of
eye disorders.  Products in the ophthalmic surgical line include intraocular
lenses, phacoemulsification systems, viscoelastics, microkeratomes and related
products used in cataract and refractive surgery.  AMO owns or has the rights
to such ophthalmic surgical product brands as ReZoom(TM), Phacoflex(R),
Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM)
intraocular lenses, Sovereign(R) and Sovereign(R) Compact(TM)
phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and
Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the
Baerveldt(R) glaucoma shunt.  Products in the contact lens care line include
disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting
drops.  Among the contact lens care product brands the company possesses are
COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F,
Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R)
and blink(TM) branded products.  Amadeus is a licensed product of, and a
trademark of, SIS, Ltd.  AMO is based in Santa Ana, California, and employs
approximately 3,000 worldwide.  The company has operations in about 20
countries and markets products in approximately 60 countries.  For more
information, visit the company's Web site at http://www.amo-inc.com/.

Forward-Looking Statements

Statements in this press release regarding Mr. Mazzo's statements, new product
benefits, and any other statements that refer to AMO's estimated or anticipated
future results are forward-looking statements.  All forward- looking statements
in this press release reflect AMO's current analysis of existing trends and
information and represent AMO's judgment only as of the date of this press
release.  Actual results may differ from current expectations based on a number
of factors affecting AMO's businesses, including but not limited to unexpected
changes in competitive, regulatory and market conditions, AMO's ability to
obtain adequate product supply and product successful collaborative efforts,
unexpected litigation or intellectual property issues, and the uncertainties
associated with market acceptance of new products.  Therefore, the reader is
cautioned not to rely on these forward-looking statements.  AMO disclaims any
intent or obligation to update these forward-looking statements.

Additional information concerning these and other risk factors may be found in
previous financial press releases issued by AMO.  AMO's public periodic filings
with the Securities and Exchange Commission, including the discussion under the
heading "Certain Factors and Trends Affecting AMO and its Businesses" in AMO's
2004 Form 10-K filed in March 2005 include information concerning these and
other risk factors.  Copies of press releases and additional information about
AMO are available at http://www.amo-inc.com/, or you can contact the AMO
Investor Relations Department by calling 714-247-8348.

   Advanced Medical Optics, Inc.
   Investors:
   Sheree Aronson
   [phone]
   

   Media:
   Steve Chesterman
   [phone]
   

http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO

http://photoarchive.ap.org/

DATASOURCE: Advanced Medical Optics, Inc.



CONTACT:  Investors, Sheree Aronson, [phone],

, or Media, Steve Chesterman, [phone],

, both of Advanced Medical Optics, Inc.



Web site:  http://www.amo-inc.com/ 

Copyright